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Abstract It is expected that rapid genetic counseling and
testing (RGCT) will lead to increasing numbers of breast
cancer (BC) patients knowing their BRCA1/2 carrier status
before primary surgery. Considering the potential impact of
knowing one’s status on uptake and timing of risk-reducing
contralateral mastectomy (RRCM), we aimed to evaluate
trends over time in RRCM, and differences between car-
riers identified either before (predictively) or after (diag-
nostically) diagnosis. We collected data from female
BRCA1/2 mutation carriers diagnosed with BC between
1995 and 2009 from four Dutch university hospitals. We
compared the timing of genetic testing and RRCM in re-
lation to diagnosis in 1995–2000 versus 2001–2009 for all
patients, and predictively and diagnostically tested patients
separately. Of 287 patients, 219 (76 %) had a diagnostic
BRCA1/2 test. In this cohort, the median time from diag-
nosis to DNA testing decreased from 28 months for those
diagnosed between 1995 and 2000 to 14 months for those
diagnosed between 2001 and 2009 (p\ 0.001). Similarly,
over time women in this cohort underwent RRCM sooner
after diagnosis (median of 77 vs. 27 months, p = 0.05).
Predictively tested women who subsequently developed
BC underwent an immediate RRCM significantly more
often than women who had a diagnostic test (21/61, 34 %,
vs. 13/170, 7.6 %, p\ 0.001). Knowledge of carrying a
BRCA1/2 mutation when diagnosed with BC influenced
decisions concerning primary surgery. Additionally, in
more recent years, women who had not undergone pre-
dictive testing were more likely to undergo diagnostic
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DNA testing and RRCM sooner after diagnosis. This
suggests the need for RGCT to guide treatment decisions.
Keywords BRCA1  BRCA2  Breast neoplasms  Risk
reducing mastectomy
Introduction
Female BRCA1 or BRCA2 gene mutation carriers have an
increased risk of developing breast cancer of 27–88 %, and
a maximum lifetime risk of developing ovarian cancer of
6–59 % [1, 2]. Once diagnosed with unilateral breast
cancer, BRCA1/2 mutation carriers have a 16–55 % risk of
developing contralateral breast cancer within 25 years,
depending on, among other factors, age at first diagnosis
and the mutated gene [3, 4].
In the case of a favorable disease stage and prognosis,
mutation carriers diagnosed with breast cancer may opt for
a risk reducing contralateral mastectomy (RRCM), which
reduces the risk of contralateral breast cancer by more than
90 %, with increasing evidence of improved breast cancer
specific survival [5–9]. The reported uptake of RRCM in
such women ranges from 18 to 65 % [10–13]. The period
of follow-up in these studies varied between a few months
to several years after genetic test disclosure or breast
cancer diagnosis.
Genetic testing of the BRCA1/2 genes became available
from 1994 onwards. In current practice, breast cancer pa-
tients at risk of having hereditary cancer are typically re-
ferred for genetic counseling and diagnostic DNA testing
after their primary treatment [14–17]. In such cases, af-
fected carriers may consider undergoing a delayed RRCM
[18]. Unaffected women who become aware of their carrier
status via a predictive DNA test (i.e. while still asymp-
tomatic) and subsequently develop breast cancer, may
consider an immediate RRCM (i.e. at the time of the
therapeutic surgery).
However, genetic counseling and testing (GCT) can also
be offered to high-risk women between breast cancer
diagnosis and primary surgical treatment (rapid genetic
counseling and testing, or RGCT). Being aware of one’s
carrier status may influence treatment decisions, including
type of surgery, use of adjuvant radiotherapy and whether
to undergo an immediate RRCM [19–21]. Such knowledge
may be particularly important for high risk women who are
determined not to carry a BRCA1/2 mutation, as their risk
of developing contralateral breast cancer may be substan-
tially lower than initially suspected [4, 22, 23].
It is expected that RGCT will become widely available
in the near future. Information on uptake and timing of
prophylactic measures chosen by carriers diagnosed with
breast cancer with a favorable prognosis is therefore in-
creasingly relevant. Such information can help breast
cancer specialists to better understand the place of genetic
testing in the clinical pathway of breast cancer diagnosis
and treatment, and ultimately can contribute to optimal
multidisciplinary treatment and care of women with breast
cancer [13, 22, 24].
The objective of the current study was to describe trends
over the years 1995–2009 in the timing of genetic testing
and of prophylactic mastectomy in breast cancer patients
carrying a BRCA1/2 mutation. More specifically, our aims
were to describe (1) the timing of genetic testing in relation
to breast cancer diagnosis; (2) the uptake of immediate
RRCM (i.e., at the time of breast cancer surgical therapy)
and of delayed RRCM; and (3) the timing of RRCM in
relation to diagnosis.
Materials and methods
Study population
The Dutch HEBON study (Hereditary Breast and Ovarian
cancer study, the Netherlands) is a retrospective cohort
study of members of families with a BRCA1 or BRCA2
mutation from 1994 onwards, with a prospective follow-up
[25]. The HEBON study was approved by the medical
ethical committees of all centers that recruited patients, and
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all individuals provided informed consent. The database
includes information on DNA test results, occurrence of
cancer, treatment, and risk-reducing surgery. BRCA1/2
mutation testing could be performed before (i.e., predic-
tive) or after breast cancer diagnosis (i.e., diagnostic)
(supplementary Figure 1). Within the HEBON-database,
data on tumor characteristics and treatment were available
for a subset of 329 female BRCA1/2 mutation carriers who
were diagnosed with breast cancer (both in situ and inva-
sive) from 1995 onwards and were treated in the Erasmus
University Medical Center (Erasmus MC) Cancer Institute,
the Netherlands Cancer Institute (NKI), the University
Medical Center Utrecht (UMCU) or the Leiden University
Medical Center (LUMC), and were counseled in the de-
partments of clinical genetics in those hospitals. Of those
329 carriers, 287 women had no distant metastases and/or
other type(s) of cancer at time of breast cancer diagnosis,
were a proven BRCA1/2 mutation carrier, had date of DNA
test result available, and had type of breast cancer surgery
available, and could therefore be included in the study.
Exclusion criteria for choice of RRCM
For questions concerning choice of immediate RRCM,
exclusion criteria were: (e) synchronous bilateral breast
cancer; and (f) breast cancer after a prophylactic bilateral
mastectomy; together n = 56. For questions concerning
choice of delayed RRCM, additional exclusion criteria
were: (g) diagnosis of (metastases of) other type(s) of
cancer at time of DNA test result; (h) having received
treatment and counseling in the LUMC due to too many
missing data on prophylactic mastectomy; (i) missing data
on RRCM; and (j) having had a RRCM before contralateral
breast cancer diagnosis, i.e., being diagnosed with breast
cancer despite having undergone a RRCM; together
n = 80. A contralateral mastectomy without information
whether it was prophylactic or therapeutic was considered
a RRCM (n = 1).
An immediate RRCM is defined as removal of the
contralateral breast at the same date as the therapeutic
mastectomy. Delayed RRCM is defined as removal of the
contralateral breast at some time after the primary surgery.
In case of a prior breast conserving surgery, the ipsilateral
breast is removed as well.
Data collection
For the current study, the following data were retrieved
from the HEBON-database: date of birth; tumor charac-
teristics [ductal carcinoma in situ (DCIS) or invasive breast
cancer, TNM stage, unilateral or bilateral breast cancer,
date of diagnosis]; history of other cancers; mutated gene
(BRCA1 or BRCA2); date of DNA test result; type of
surgical treatment for breast cancer; date(s) of breast can-
cer surgery/surgeries; type(s) and date(s) of prophylactic
breast surgery/surgeries; and hospital where treatment and
DNA-testing were performed. Tumor stage was catego-
rized according to the TNM classification as included in the
breast cancer guideline 2.0 (2012) of the Comprehensive
Cancer Center the Netherlands [16].
Statistical analyses
Chi square tests were used to compare choice of immediate
and delayed RRCM for women who underwent a predictive
DNA test versus those who had a diagnostic test, for
women who were treated in 1995–2000 versus 2001–2009
separately. We chose to analyze these two time periods
because, from 2001 onwards, in the Netherlands increased
awareness among breast cancer specialists and probably
also patients had led to larger numbers of breast cancer
patients being referred for genetic counseling and testing,
and GCT had become more conventional. With this divi-
sion, the number of patients in both time periods still is
relatively well distributed. Mann–Whitney U tests were
used to compare time between breast cancer diagnosis and
DNA testing for the time periods 1995–2000 versus
2001–2009. Kaplan–Meier analyses were used to compare
time between first breast cancer diagnosis and risk reducing
surgery, and between DNA test result and delayed risk
reducing surgery for the time periods 1995–2000 versus
2001–2009. End of time under follow-up was defined as
either RRCM, contralateral breast cancer diagnosis, or end
of follow-up, whatever came first. Patients who had a
predictive test and those who had a diagnostic test were
analyzed separately, when applicable.
In addition, Cox regression was used to compare the time
between diagnosis and RRCM for both time periods (cate-
gorical 1995–2000 vs. 2001–2009) adjusted for age at diag-
nosis (continuous variable in years), predictive versus
diagnostic testing (categorical variable), nodal status (cate-
gorical positive vs. negative), and use of chemotherapy
(categorical yes vs. no). Patients who had a predictive test and
those who had a diagnostic test were also analyzed separately.
Results
Clinical and sociodemographic characteristics
of the sample
From the HEBON subset of 329 women who were diag-
nosed with breast cancer between 1995 and 2009 in one of
the participating hospitals, we included 287 BRCA1/2
mutation carriers. The majority of the patients (77 %) had a
BRCA1 mutation (Table 1).
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One hundred eighty-three BRCA1/2 mutation carriers
(64 %) were diagnosed with breast cancer between 1995
and 2000, and 104 (36 %) between 2001 and 2009. Mean
age at breast cancer diagnosis was 42.0 years for patients
diagnosed between 1995 and 2000, compared to 44.4 years
for those diagnosed between 2001 and 2009 (p = 0.04).
Other sample characteristics are described in Table 1. Of
note, exclusion of DCIS cases did not alter significantly
any of the findings presented in this paper (data not
shown).
Timing of genetic counseling and testing (GCT)
Of all patients, 219 (76 %) had a diagnostic DNA test and
68 (24 %) had a predictive DNA test. Of those who had a
diagnostic test, 4 received their DNA test results before
primary surgery (i.e., had RGCT). Predictive DNA testing
increased from 12 % for those diagnosed between 1995
and 2000 to 44 % for those diagnosed between 2001 and
2009 (p\ 0.001) (Table 1). For patients who had a diag-
nostic test, the median time between breast cancer diag-
nosis and DNA test result decreased from 28 months
[range 0–143; mean (SD) 35.7 (31.2)] for patients diag-
nosed between 1995 and 2000 to 14 months [range 0–80,
mean (SD) 18.8 (16.5)] for those diagnosed between 2001
and 2009 (p\ 0.001).
Uptake of risk reducing mastectomy
Immediate risk reducing contralateral mastectomy at the
time of breast cancer surgery Of the 231 patients for
whom these data were available, 34 (14.7 %) had an im-
mediate RRCM (Table 2 and supplementary flowchart).
Considering the complete time period 1995–2009, breast
cancer patients who had a predictive test opted for an
immediate RRCM significantly more often than patients
who had a diagnostic test (34.4 vs. 7.6 %, p\ 0.001); this
difference was seen in the time period 1995–2000 as well
as in 2001–2009 (Table 2). Within the subgroup of pre-
dictively tested patients who underwent an immediate
RRCM, there was no significant difference (p = 0.23)
observed in choice of immediate RRCM between 1995 and
2000 (9/20, 45.0 %) versus 2001–2009 (12/41, 29.3 %).
Delayed risk reducing contralateral mastectomy after
completion of primary breast cancer therapy Of the 151
patients from the NKI, UMCU and Erasmus MC for whom
relevant data were available, 73 (48.3 %) had a delayed
RRCM after breast cancer diagnosis (Table 2). The uptake
of a delayed RRCM was not significantly different between
patients who had a predictive DNA test and those who had a
diagnostic DNA test in neither of the time periods (Table 2).
However, within the subgroup of patients who had a diag- T
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nostic test, patients who received DNA test results within a
year after BC diagnosis opted for a delayed RRCM sig-
nificantly more often than patients who received DNA test
results more than a year after BC diagnosis [26/37 (70.3 %)
versus 31/82 (37.8 %), p = 0.001]. This difference was also
seen in the separate time periods [16/24 (66.7 %) versus
28/71 (39.4 %), p = 0.02 in 1995–2000, and 10/13 (76.9 %)
versus 3/11 (27.3 %), p = 0.02 in 2001–2009].
Timing of risk reducing contralateral mastectomy
Overall, 50.5 % of patients who were diagnosed between
1995 and 2000 had an immediate or delayed RRCM within
5 years since breast cancer diagnosis, compared with
68.1 % for patients diagnosed between 2001 and 2009
(Fig. 1a). However, there was an indication for a difference
between predictively and diagnostically tested patients,
with a decrease of 80.0–69.5 % in patients who had a
predictive test (Fig. 1b), and an increase of 44.7–65.4 % in
patients who had a diagnostic test (Fig. 1c). In the Cox
analyses, adjusted for age at diagnosis, nodal status and
chemotherapy, of those diagnosed in 2001–2009, predic-
tively tested patients were less likely, and diagnostically
tested patients were more likely, to have had a RRCM than
those diagnosed in 1995–2000, although both differences
were not significant (Table 3). In the same multivariate
model, older patients who had a predictive test were less
likely to undergo a RRCM than younger patients who had a
predictive test (HR 0.95, 95 % CI 0.92–0.99, p = 0.01).
In the Cox analyses for predictively and diagnostically
tested patients together, adjusted for age at diagnosis, time
period of diagnosis, nodal status and chemotherapy, patients
who had a predictive test were more likely to have had a
RRCM than patients who had a diagnostic test, with a hazard
ratio of 4.49 (95 % CI 2.5–8.1, p\ 0.001). In addition, older
patients were again less likely to undergo a RRCM than
younger patients; but only significantly so if they had a
predictive test (HR 0.96, 95 % CI 0.94–0.98, 0\ 0.001).
For diagnostically tested patients, the mean time between
DNA test results and delayed RRCM decreased over time
from 108.8 months (SD 5.1) in 1995–2000 to 67.3 months in
2001–2009 (SD 5.9, p\ 0.001) (Fig. 1d). There was an in-
crease in the percentage of patients who had a RRCM 5 years
after DNA test result from 17.5 to 37.5 %.
Discussion
Our data show that, in the time period 2001–2009, BRCA1/
2 mutation carriers who were not aware of their carrier
status at the time of their breast cancer diagnosis, had di-
agnostic DNA testing sooner after diagnosis than those in
the time period 1995–2000. Additionally, the proportion of
breast cancer patients who had predictive DNA testing
increased significantly over time. This shift towards more
predictive testing probably reflects the greater availability,
completeness and acceptance of DNA testing over time,
and a decrease in the time required to report test results.
However, a survival bias cannot be ruled out, as patients
must have survived long enough to be recruited in the
HEBON study. Importantly, our data also clearly indicate
that women known to be carrier before breast cancer di-
agnosis opted significantly more often for an immediate
RRCM than those who had a DNA test after cancer diag-
nosis. Apparently, for the decision to undergo an imme-
diate RRCM, DNA test results are more important to both
patients and treating specialists than being at risk of having
hereditary breast cancer only. This is relevant, since there
are concerns that RGCT will increase the percentage of
women opting for an immediate RRCM not only in carri-
ers, but also in women without a pathogenic mutation.
However, this finding suggests that it is unlikely for RGCT
to make women without a mutation opt more often for an
immediate RRCM. There was, however, no significant in-
crease over time in the frequency of RRCM in patients who
had a predictive test. Similarly, no trend over time was seen
for the uptake of delayed RRCM in both patients who had a
predictive test and those who had a diagnostic test. Patients
who had a diagnostic test opted for RRCM sooner after
breast cancer diagnosis in the more recent time period.
Overall, 34 % of the patients who developed unilateral
breast cancer after a predictive DNA test had an imme-
diate RRCM. This is only slightly less than the percentage
reported by Cortesi et al.[19], who observed that 42 % of
women who became aware of their carrier status within
1 month after breast cancer diagnosis opted for a RRCM,
although it is not clear whether this was performed at the
time of primary surgery or thereafter. As to our knowl-
edge, no other studies provide explicit information on the
timing of DNA testing (i.e., predictive or diagnostic),
which makes it difficult to compare results. However, two
American studies provide some information. King et al.
[26] observed that 54 % of affected carriers had a RRCM
within 1 year after diagnosis. Chung et al. observed that
13/16 (81 %) of women diagnosed with breast cancer
between 1995 and 2008 who were BRCA1/2 mutation
carriers, had an immediate RRCM. Contrary to our find-
ings, they observed an increase in the frequency of im-
mediate RRCM over time, in both mutation carriers and in
women without (knowledge of) a BRCA1/2 mutation [27].
The increase in RRCMs over time appears to be more
common in the United States, and particularly in women
without an increased risk of contralateral breast cancer
[26, 28–30].
In line with data from an earlier study [12], 48 % of
affected carriers in our study had a delayed RRCM.
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Interestingly, patients who had a diagnostic DNA test and a
delayed RRCM tended to opt for this surgery sooner after
breast cancer diagnosis in the more recent time period
(from a median of 77–27 months). This may be explained,
at least in part, by the fact that the time between breast
cancer diagnosis and DNA test results decreased in this
group from 28 months in patients diagnosed 1995–2000 to
14 months in patients diagnosed 2001–2009. It is unclear
whether this reflects primarily an earlier decision to un-
dergo RRCM, reduced waiting times for surgery or dif-
ferences in advice from the multidisciplinary team.
Our study had several limitations that should be noted.
Women treated for breast cancer in 1995–2000 differed
from those treated in 2001–2009 in age at diagnosis, fol-
low-up time, and possibly also were subject to survival
bias. Second, our sample with data available on risk re-
ducing mastectomy was rather small. Third, although there
may have been between-hospital variation in the criteria
used for performing a RRCM (e.g., disease-free time since
diagnosis or nodal status), use of MRI at breast cancer
diagnosis, or availability and quality of breast reconstruc-
tion, we did not have data to address this question. Finally,
we analyzed BRCA1 and BRCA2 mutation carriers to-
gether, also in view of the small numbers of BRCA2 mu-
tation carriers. However, we do not expect significant
differences between BRCA1 and BRCA2 mutation carriers
Fig. 1 Kaplan Meier curves of cumulative RRCM incidence a Cu-
mulative RRCM (immediate or delayed) incidence from time of
breast cancer diagnosis comparing two time periods in both predic-
tively and diagnostically tested patients b Cumulative RRCM
(immediate or delayed) incidence from time of breast cancer
diagnosis comparing two time periods in patients who had a
predictive test c Cumulative RRCM (immediate or delayed) incidence
from time of breast cancer diagnosis comparing two time periods in
patients who had a diagnostic test d Cumulative delayed RRCM
incidence from time of DNA test result in patients who had a
diagnostic test. *RRCM risk reducing contralateral mastectomy
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in choice of (risk reducing) breast surgery, since both
groups probably received similar information about the risk
of (contralateral) breast cancer.
Our study also has a number of noteworthy strengths.
First, unlike most earlier studies, we have reported results
on the choice of RRCM separately for mutation carriers
who developed breast cancer following a predictive DNA
test, and those mutation carriers who had a diagnostic DNA
test following their breast cancer diagnosis. Second, we
investigated trends over time; something that was not done
in some earlier, large studies of risk reducing surgery in
BRCA1/2 mutation carriers with breast cancer [10, 11, 31].
Implications for daily practice
Our results indicate that knowledge of one’s carrier status
at the time of breast cancer diagnosis is important in de-
cisions about risk reducing mastectomy, and that for those
without this knowledge, especially in young breast cancer
patients, there may be a need for RGCT to guide treatment
decisions.
Since the use of neo-adjuvant chemotherapy is in-
creasing, it is expected that an increasing number of pa-
tients will be able to receive DNA test results before
primary surgery and incorporate these in their treatment
decisions. With such information at hand, both breast
cancer specialists and their high-risk breast cancer patients
will hopefully be able to make more informed decisions
about the most appropriate, individualized treatment.
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